50 completed, 16 unknown, 8 recruiting, 4 terminated. 81 Phase 1, 30 Phase 2.
Follow Paralysis: new trials by email Literature Review of Paralysis trials Research Report on Paralysis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single Dose 4-Aminopyridine for Diagnosing Recurrent Laryngeal Nerve Paralysis Continuity After Trauma 4-Aminopyridine - Vocal Cord Paralysis, Recurrent Laryngeal Nerve Palsy | Phase 1 | Not yet recruiting | Milton S. Hershey Medical Center | 50 | 2026-12-01 | 2026-09-21 |
| Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial Tributyrin, Placebo - Parkinson Disease, Multiple System Atrophy | Phase 1 / Phase 2 | Recruiting | Prabesh Kanel | 15 | 2026-10-01 | 2026-11-05 |
| Psilocybin to Treat Depression in Spinal Cord Injury Psilocybin (Usona Institute) - Spinal Cord Injury, Depression - Major Depressive Disorder | Phase 1 / Phase 2 | Recruiting | James J. Peters Veterans Affairs Medical Center | 30 | 2026-08-06 | 2026-08-10 |
| Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability Psilocybin (Usona Institute) - Stroke, Chronic Stroke | Phase 1 | Recruiting | Johns Hopkins University | 20 | 2026-02-09 | 2026-02-13 |
| Trial of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease or Primary Tauopathies ARO-MAPT-SC, Placebo - Alzheimer Disease, Tauopathies | Phase 1 / Phase 2 | Recruiting | Arrowhead Pharmaceuticals | 160 | 2025-11-18 | 2026-11-10 |
| A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury OPC1 - Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic | Phase 1 | Recruiting | Lineage Cell Therapeutics, Inc. | 10 | 2025-06-30 | 2026-02-12 |
| Facilitating Neuroplastic Changes of Acute Stroke Survivors Motor relearning training, Passive stretching, Gamed-based active movement training - Stroke | Phase 1 / Phase 2 | Recruiting | University of Maryland, Baltimore | 68 | 2025-06-01 | 2026-07-23 |
| Melpida: Recombinant Adeno-associated Virus (Serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) MELPIDA - Spasticity, Muscle, Microcephaly | Phase 1 / Phase 2 | Recruiting | Elpida Therapeutics SPC | 4 | 2023-02-15 | 2026-07-08 |
| Cord Blood Cells in Patients With Acute SCI Multiple systemic (i.v.) administration of allogenic non-related group- and rhesus-compatible mononuclear cord blood cells, Control vehicle (sterile saline) - Spinal Cord Injury, Acute | Phase 1 / Phase 2 | Unknown | Sklifosovsky Institute of Emergency Care | 80 | 2022-12-05 | 2023-01-20 |
| A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN) SBT101 Treatment - AMN, AMN Gene Mutation | Phase 1 / Phase 2 | Terminated | SwanBio Therapeutics, Inc. | 9 | 2022-11-17 | 2026-08-26 |
| Test-retest Study With [18F]PI-2620 in PSP-RS and NDC [18F]-PI2620 - Progressive Supranuclear Palsy | Phase 1 | Completed | Life Molecular Imaging GmbH | 15 | 2022-03-10 | 2026-10-26 |
| Evaluation of [18F]APN-1607 as a PET Biomarker [18F] APN-1607 - Progressive Supranuclear Palsy, Healthy Volunteers | Phase 1 | Completed | Invicro | 12 | 2021-05-25 | 2025-02-20 |
| Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy antisense oligonucleotide, placebo - Progressive Supranuclear Palsy (PSP) | Phase 1 | Completed | Novartis Pharmaceuticals | 59 | 2021-02-16 | 2025-12-24 |
| Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks Tolfenamic Acid, Placebos - Progressive Supranuclear Palsy | Phase 1 / Phase 2 | Unknown | NeuroTau, Inc. | 24 | 2021-01-01 | 2020-02-05 |
| Low or High Botox Dilution for the Hemiplegic Gait? Botulinum toxin, gait analysis - Post Stroke Spastic Hemiplegia | Phase 1 | Recruiting | University of Ioannina | 20 | 2020-11-20 | 2024-12-06 |
| A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy UCB0107 (bepranemab) - Progressive Supranuclear Palsy | Phase 1 | Active not recruiting | UCB Biopharma SRL | 19 | 2020-11-16 | 2026-08-03 |
| Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity [18F]-PI2620 - Alzheimer Disease, Progressive Supranuclear Palsy | Phase 1 | Completed | Life Molecular Imaging GmbH | 10 | 2020-11-12 | 2026-10-26 |
| A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) bepranemab, Placebo - Progressive Supranuclear Palsy | Phase 1 | Completed | UCB Biopharma SRL | 25 | 2019-12-03 | 2023-12-01 |
| A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease KL1333, Placebo Oral Tablet - Mitochondrial Diseases, Mitochondrial Respiratory Chain Deficiencies | Phase 1 | Completed | Abliva AB | 72 | 2019-03-18 | 2021-10-20 |
| Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 ABBV-8E12 - Progressive Supranuclear Palsy (PSP) | Phase 1 | Completed | AbbVie | 3 | 2018-04-17 | 2019-12-03 |
Showing 20 of 81. Sign in to see all of them.
Supranuclear Palsy, Progressive (23) · Spinal Cord Injuries (17) · Gastroparesis (16) · Quadriplegia (16) · Paraplegia (14) · Stroke (14) · Hemiplegia (11) · Alzheimer Disease (4) · Corticobasal Degeneration (4) · Paresis (4) · Diabetes Mellitus (3) · Parkinson Disease (3) · Pick Disease of the Brain (3) · Tauopathies (3)
Pathological Conditions, Signs and Symptoms (81) · Signs and Symptoms (81) · Neurologic Manifestations (79) · Nervous System Diseases (66) · Central Nervous System Diseases (57) · Brain Diseases (41) · Cranial Nerve Diseases (27) · Neurodegenerative Diseases (25) · Basal Ganglia Diseases (24) · Eye Diseases (24) · Movement Disorders (24) · Ocular Motility Disorders (24) · Ophthalmoplegia (24) · Tauopathies (20)
N-(3-fluorophenyl)-1-((4-(((3S)-3-methyl-1-piperazinyl)methyl)phenyl)acetyl)-4-piperidinamine (3) · ((18)F)PI-2620 (2) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (2) · Buspirone (2) · Constraint Induced Movement Therapy (2) · Psilocybin (2) · florbetapir (2) · gosuranemab (2) · 4-Aminopyridine (1) · Acetylcarnitine (1) · Acupuncture Therapy (1) · Body Piercing (1) · Botulinum Toxins (1) · Creb3l2 protein, rat (1) · Gait Analysis (1)
GlaxoSmithKline (5) · James J. Peters Veterans Affairs Medical Center (3) · University of California, San Francisco (3) · Biogen (2) · Invicro (2) · Johns Hopkins University (2) · Life Molecular Imaging GmbH (2) · Lineage Cell Therapeutics, Inc. (2) · Royal Adelaide Hospital (2) · UCB Biopharma SRL (2) · W. Dalton Dietrich (2) · AMES Technology (1) · AbbVie (1) · Abliva AB (1) · Adam Boxer (1)
United States (50) · United Kingdom (8) · Germany (5) · Australia (4) · Belgium (4) · Canada (4) · Spain (4) · Israel (2) · Russia (2) · China (1) · Colombia (1) · Denmark (1) · Finland (1) · Greece (1) · Italy (1)
Adam Boxer, MD, PhD (3) · Allan Levi, MD, PhD (2) · Andrew Stephens, MD, PhD (2) · James Guest, MD, PhD (2) · Karen L Jones, PhD (2) · Miroslav Radulovic, MD (2) · Adam L. Boxer, M.D., Ph.D. (1) · Adil Bharucha, MBBS, MD (1) · Alexander Averyanov, MD (1) · Andrew Nemecek, MD (1) · Barry Oken, MD (1)
PMID 19074686, PMID 19154823, PMID 19615045, PMID 19666345, PMID 19965145, PMID 21381984, PMID 21575185, PMID 21652288, PMID 22254998, PMID 22275632, PMID 22531737, PMID 22692932, PMID 22738299, PMID 22961573, PMID 23366834, PMID 23366943, PMID 23639598, PMID 23844986, PMID 24119615, PMID 24284925, PMID 24438512, PMID 25148846, PMID 25527487, PMID 25570772, PMID 26084322, PMID 27160012, PMID 28225648, PMID 28782145, PMID 28899825, PMID 29760737, PMID 31122495, PMID 31710340, PMID 31785831, PMID 32407247, PMID 32493977, PMID 33175411, PMID 33438658, PMID 33647530, PMID 34712113, PMID 35364569, PMID 35460043, PMID 35901693, PMID 36772802, PMID 38561341, PMID 39626671, PMID 41389437, PMID 41491634, PMID 8079356, PMID 8355728
1RC1EB010915-01 (1), 2019 (1), I01RX000528 (1), K01HD069504 (1), P01DK068055 (1), R01NS061304 (1), R43AT004489 (1), R43NS067694 (1), UL1RR024150 (1)